Clinical studies with high flow nasal cannula oxygen delivery in 2015

  • David Sotello Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock TX
  • Hawa Edriss Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock TX
  • Kenneth Nugent Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock TX
Keywords: nasal cannula, oxygen therapy

Abstract

HFNC devices can provide humidified oxygen at high flow rates with high FiO2s.  This method of oxygen delivery appears to be more comfortable than using noninvasive ventilation, and it does improve oxygenation, reduce respiratory rates, and reduce the sense of dyspnea.  This modality has been studied most in patients with acute hypoxemic respiratory failure. The study reported by Frat et al provides good evidence that patients with moderate to severe respiratory failure (PaO2/FiO2 < 200) may benefit the most.

The more complex the patient’s underlying medical problems are the more likely HFNC therapy to fail

Downloads

Download data is not yet available.

Author Biography

David Sotello, Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock TX
MD, pulmonary physician, expertise- clinical projects, ICU, COPD, general pulmonary medicine
Published
2016-04-08
How to Cite
Sotello, D., Edriss, H., & Nugent, K. (2016). Clinical studies with high flow nasal cannula oxygen delivery in 2015. The Southwest Respiratory and Critical Care Chronicles, 4(14), 17-22. Retrieved from https://pulmonarychronicles.com/index.php/pulmonarychronicles/article/view/268